Category Archives : News

Home  >>  News

PEPperPRINT granted new US patent

On July 18, 2018, Posted by , In News, By , With Comments Off on PEPperPRINT granted new US patent

PEPperPRINT latest patent covers a novel method for producing high-density peptide microarrays PEPperPRINT is pleased to announce that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 9,925,509 covering a method for the generation of high-density peptide microarrays by means of a combinatorial laser induced forward…

EMBL scientists show that mammalian life begins differently than we thought

On July 16, 2018, Posted by , In News, By , , With Comments Off on EMBL scientists show that mammalian life begins differently than we thought

It was long thought that during an embryo’s first cell division, one spindle is responsible for segregating the embryo’s chromosomes into two cells. EMBL scientists now show that in mice, there are actually two spindles, one for each set of parental chromosomes, meaning that the genetic information from each parent…

HITS: New computational method for drug discovery

On July 12, 2018, Posted by , In News, By , , With Comments Off on HITS: New computational method for drug discovery

HITS researchers developed tauRAMD, a tool to predict drug-target residence times from short simulations. The method is illustrated on the cover page of July 2018 issue of the Journal of Chemical Theory and Computation, software is freely available. The graphical image used for the cover of the JCTC . Image:…

DKFZ: Mechanism of action of a diabetes drug differs between males and females

On July 11, 2018, Posted by , In News, By , , With Comments Off on DKFZ: Mechanism of action of a diabetes drug differs between males and females

Most diabetes medications do not attack the cause of the disease. Glitazones are different: they improve insulin sensitivity and can promote the conversion of unhealthy white adipose tissue into fat-burning beige adipocytes. However, due to their side effects, they are hardly used. Scientists from the German Cancer Research Center are…

DKFZ: Brain cancer – Typical mutation in cancer cells stifles immune response

On July 11, 2018, Posted by , In News, By ,, , With Comments Off on DKFZ: Brain cancer – Typical mutation in cancer cells stifles immune response

The exchange of a single amino acid building block in a metabolic enzyme can lead to cancer. In addition, it can impair the immune system, scientists from the German Cancer Research Center (DKFZ), the University Hospitals in Mannheim and Heidelberg, and the German Cancer Consortium now report. It thus blocks…

New member: Welcome in our cluster to HITS – Heidelberg Institute for Theoretical Studies

On July 11, 2018, Posted by , In News, By , With Comments Off on New member: Welcome in our cluster to HITS – Heidelberg Institute for Theoretical Studies

We are happy to welcome in our cluster the Heidelberg Institute for Theoretical Studies: The Heidelberg Institute for Theoretical Studies (HITS) was established in 2010 by the physicist and SAP co-founder Klaus Tschira (1940-2015) and the Klaus Tschira Foundation as a private, non-profit research institute. HITS conducts basic research in…

New member: Welcome in our cluster to Drees & Sommer

On July 10, 2018, Posted by , In News, By , With Comments Off on New member: Welcome in our cluster to Drees & Sommer

We are happy to welcome in our cluster Drees & Sommer. Drees & Sommer is an innovative partner for consulting, planning, construction and operation. For more than 45 years, the company has been supporting public- and private-sector owners and investors in all aspects of real estate. Managed by partners and…

New member: Welcome in our cluster to ERA Consulting

On July 5, 2018, Posted by , In News, By , With Comments Off on New member: Welcome in our cluster to ERA Consulting

We are happy to welcome in our cluster ERA Consulting. The ERA Consulting Group is one of the longest established and most experienced regulatory affairs and product development consulting groups serving the biopharmaceutical industry. “Our expertise covers quality, nonclinical and clinical aspects, both from the regulatory and development strategy perspective….

EMBL: Combining antibiotics changes their effectiveness

On July 5, 2018, Posted by , In News, By , With Comments Off on EMBL: Combining antibiotics changes their effectiveness

The effectiveness of antibiotics can be altered by combining them with each other, non-antibiotic drugs or even with food additives, EMBL researchers show. Depending on the bacterial species, some combinations stop antibiotics from working to their full potential whilst others begin to defeat antibiotic resistance, report EMBL researchers and collaborators…

Viscofan BioEngineering: Phase-I-trial approved for novel stem cell therapy for patients with ischemic cardiomyopathy

On July 4, 2018, Posted by , In News, By ,, , With Comments Off on Viscofan BioEngineering: Phase-I-trial approved for novel stem cell therapy for patients with ischemic cardiomyopathy

Viscofan BioEngineering, the biomedical business unit of the world market leader for collagenous sausage casings Viscofan announced today that the Spanish Agency for Medicines (AEMPS) has given green light to carry out a clinical phase-I-trial with Viscofan BioEngineering’s first product for regenerative medicine. The novel therapy consisting of stem cells…